Patents by Inventor Yusuke SHUCHI

Yusuke SHUCHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD37 ANTIBODY-DRUG CONJUGATE
    Publication number: 20250025571
    Abstract: It is an object to provide an antibody specifically binding to CD37-positive tumor cells such as malignant B-cell lymphoma, an antibody-drug conjugate comprising the antibody, a pharmaceutical composition having therapeutic effects on a tumor using the antibody, a method for treating a tumor using the aforementioned pharmaceutical composition, a method for producing the antibody, and a method for producing the antibody-drug conjugate, and the like. The present invention provides an anti-CD37 antibody-drug conjugate in which an antibody is conjugated to a drug linker represented by the following formula (wherein A represents a connecting position to the antibody) by a thioether bond, specifically, a humanized anti-CD37 antibody having internalization ability and an antibody-drug conjugate containing the antibody.
    Type: Application
    Filed: October 7, 2024
    Publication date: January 23, 2025
    Applicant: DAIICHI SAMKO COMPANY, LIMITED
    Inventors: Tomoko TERAUCHI, Yuji SHANJO, Hajime SUGAWARA, Yusuke SHUCHI, Riki GOTO
  • Anti-CD37 antibody-drug conjugate
    Patent number: 12138315
    Abstract: It is an object to provide an antibody specifically binding to CD37-positive tumor cells such as malignant B-cell lymphoma, an antibody-drug conjugate comprising the antibody, a pharmaceutical composition having therapeutic effects on a tumor using the antibody, a method for treating a tumor using the aforementioned pharmaceutical composition, a method for producing the antibody, and a method for producing the antibody-drug conjugate, and the like. The present invention provides an anti-CD37 antibody-drug conjugate in which an antibody is conjugated to a drug linker represented by the following formula (wherein A represents a connecting position to the antibody) by a thioether bond, specifically, a humanized anti-CD37 antibody having internalization ability and an antibody-drug conjugate containing the antibody.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: November 12, 2024
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tomoko Terauchi, Yuji Shinjo, Hajime Sugawara, Yusuke Shuchi, Riki Goto
  • ANTI-CD37 ANTIBODY-DRUG CONJUGATE
    Publication number: 20240165254
    Abstract: It is an object to provide an antibody specifically binding to CD37-positive tumor cells such as malignant B-cell lymphoma, an antibody-drug conjugate comprising the antibody, a pharmaceutical composition having therapeutic effects on a tumor using the antibody, a method for treating a tumor using the aforementioned pharmaceutical composition, a method for producing the antibody, and a method for producing the antibody-drug conjugate, and the like. The present invention provides an anti-CD37 antibody-drug conjugate in which an antibody is conjugated to a drug linker represented by the following formula (wherein A represents a connecting position to the antibody) by a thioether bond, specifically, a humanized anti-CD37 antibody having internalization ability and an antibody-drug conjugate containing the antibody.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 23, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMTED
    Inventors: Tomoko TERAUCHI, Yuji Shinjo, Hajime SUGAWARA, Yusuke SHUCHI, Riki GOTO